Immunome
IMNM
30 hedge funds and large institutions have $36.4M invested in Immunome in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 2 reducing their positions, and 10 closing their positions.
550% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 2
162% more call options, than puts
Call options by funds: $1.45M | Put options by funds: $553K
2.73% more ownership
Funds ownership: 20.34% → 23.07% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less funds holding
Funds holding: 35 → 30 (-5)
38% less capital invested
Capital invested by funds: $58.3M → $36.4M (-$22M)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Prentice Capital Management
Greenwich,
Connecticut
|
+$5.16M |
| 2 |
Morgan Stanley
New York
|
+$1.15M |
| 3 |
AI
Atom Investors
Austin,
Texas
|
+$818K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$451K |
| 5 |
State Street
Boston,
Massachusetts
|
+$255K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$514K |
| 2 |
HT
HAP Trading
New York
|
-$436K |
| 3 |
VF
Virtu Financial
New York
|
-$266K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$263K |
| 5 |
BIM
Baldwin Investment Management
West Conshohocken,
Pennsylvania
|
-$224K |
IMNM Hedge Fund Activity: Q4 2021 in Review
30 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q4 2021, worth a combined $36.4M — down 38% from $58.3M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of IMNM and 5 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 13 added.
The largest buyer was Prentice Capital Management, adding an estimated $5.16M. The largest seller was Millennium Management, exiting entirely with an estimated $514K sold.
- 30 institutional investors held Immunome (IMNM) as of Q4 2021, down from 35 in Q3 2021.
- Funds reported $36.4M of Immunome stock for Q4 2021, down 38% quarter-over-quarter.
- 5 funds opened new Immunome positions in Q4 2021 and 10 closed out, a net change of -5 holders.
- The largest Immunome buyer in Q4 2021 was Prentice Capital Management, an estimated $5.16M added.
- The largest Immunome seller in Q4 2021 was Millennium Management, an estimated $514K sold.
Based on aggregated 13F filings for Q4 2021.